产品描述
CPX-351 is a Liposomal-encapsulated combination of daunorubicin and cytarabine for the treatment of newly diagnosed tAML or AML with myelodysplasia-related changes (AML-MRCs).
Cas No.
1256639-86-7
分子式
C36H42N4O15
分子量
770.74
别名
Vyxeos;CPX 351;Cytarabine/daunonubicin;Daunonubicin/cytarabine
储存和溶解度
(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
